May 17, 2020

The Rise in Biologics

4 min
The European healthcare industry wouldnt be where it is today if it wasnt for continuous innovation and investment. As the region emerges from the const...

The European healthcare industry wouldn’t be where it is today if it wasn’t for continuous innovation and investment. As the region emerges from the constraints of the economic downturn, it remains imperative to ensure that investment and resources are correctly harnessed, as the average number of drugs being approved for human use has decreased significantly in recent times. 

With this decline in getting drugs to market post research and development (R&D), we should consider how we can ensure investment is used as effectively as possible.  For the European healthcare and pharma industries, trends and innovations are of high importance in achieving this.  Whether to help ensure better quality and longer life expectancy or return on investment potential, healthcare companies need to keep one step ahead of consumer requirements.  This will ensure drugs and pharmaceutical products continue to fulfil society’s demand and that supporting services mirror this requirement accordingly.

Look to the Future

Looking closely at the shift in disease patterns is a good place to start as well as considering how to manage the arguable spiralling cost of healthcare or keeping informed on developments in new markets.  More specifically, focusing on trends in past years can provide a more accurate forecast as to what is on the horizon.  Being aware of “the next big thing” is important and we want to provide some guidance on the areas to be aware of.

Biologics: Complexities

FedEx has worked in the healthcare industry for over 40 years and to ensure we continue to have the capabilities to connect healthcare and pharma companies with their customers around the globe, trend spotting is integral.

With a Pharma company’s lifeblood being its R&D pipeline, researchers have been turning to the world of ‘Biologics’ to find tomorrow’s next blockbuster.  In recent years, we’ve seen a more pronounced rise in this area – medicinal products derived from, or manufactured within, living cells –– and within the next 10-15 years’ time, we need to be aware this shift into personalised medicines will continue to grow.  By 2018, it is predicted 49 percent of the top 100 healthcare products will be biotech.  Germany and the UK are Europe’s hotspots for biotechnological development and with that comes the responsibility to continue to remain on the leading edge of innovation in this field. 

Currently, new research is taking place within this sector which will enable specific areas of the body to be targeted and treated, causing minimal side-effects elsewhere.  This means drugs can be personalised per patient group and even work with “orphan” therapeutic areas that are extremely rare.  This means European nations must seek to maintain momentum as leading locations for this field.

Biologics: A Sensitive Subject

Biologics, although innovative, are extremely fragile and sensitive.  Made from “living plant, human, animal cells or microorganisms”, most biologics are large, complex molecules and extreme care has to be taken throughout the journey from creation to end user.  Although this is a ground-breaking area, a supportive network is required, whether during the research and development stage or transportation, so the products benefits can be realised.

Temperature: Considerations

Looking at biologics in greater detail, it’s clear the transportation needs in the industry are evolving. 

Over 90 percent of all vaccines require a temperature-controlled supply chain that begins with the manufacturer and ends with the administration to the patient[1] and by 2020, it is estimated that 8 of the top 10 best-selling global drugs will require handling at +2oC to +8oC .  Reinforcing the complexities that could be faced throughout a supply chain, it is clear increased care during transportation needs to develop alongside industry innovations. 

From a logistics perspective, biologics are considered very time-and-temperature sensitive and even slight temperature changes can alter their molecular structure, rendering them ineffective or even toxic.  Driving innovation to create seamless temperature-controlled networks and sensor-based monitoring tools are in greater demand and specialised packaging that keep biological samples deep frozen, or one-click packaging solutions to keep samples cold are required even more. 

With these complex pharmaceuticals, faster transportation is needed to reduce the chance and risk of exposure.  Although the aim is speed focused, care and quality of a “network within a network” is also important as is contingency planning to maintain product reliability.  Previously, biologics were transported through numerous intermediaries, requiring frequent “stop-overs”, however now they need to be transported directly from the manufacturer to the customer.  With no intermediary required, a direct-distribution channel strategy will become standardised and due to legislation in the UK, drivers tasked with safe transportation will require certain training.

Europe: Leading the Way

Healthcare is a truly globalised industry yet a highly challenging and regulated one.  With Europe continuing to be one of the largest healthcare markets in the world, we should ensure this continues into the years ahead and we hope this look to the future will spark discussions to ensure this happens.  Adaptation and flexibility is important and as long as healthcare anod pharma companies continue to plan ahead and innovate, we are sure Europe will remain a leading region in this area and we aim to continue innovating to support it in achieving this.

The author: Toby Hay is Global Sales Manager at FedEx HealthCare Solutions

Share article

Jun 8, 2021

DHL Claim Multi-Sector Collaboration Key to Fighting COVID

3 min
Global logistics leader DHL’s new white paper highlights what supply chain professionals have learned one year into the pandemic

Since January, global logistics leader DHL has distributed more than 200 million doses of the COVID vaccine to 120+ countries around the globe. While the US and UK recently rolled out immunisation plans to most citizens, countries with less developed infrastructure still desperately need more doses. In the United Arab Emirates (UAE), which currently has one of the highest per-capita immunisation rates, the government set up storage facilities to cover domestic and international demand. But storage, as we’ve learned, is little help if you can’t transport the goods.


This is where logistics leaders such as DHL make their impact. The company built over 50 new partnerships, bilateral and multilateral, to collaborate with pharmaceutical and private sector firms. With more than 350 DHL centres pressed into service, the group operated 9,000+ flights to ship the vaccine where it needed to go. 


Public-Private Partnerships

With new pandemic knowledge, DHL just released its “Revisiting Pandemic Resilience” white paper, which examined the role of logistics and supply chain companies in handling COVID-19. As Thomas Ellman, Head of Clinical Trials Logistics at DHL, said: “The past one year has highlighted the importance of logistics and supply chain management to manage the pandemic, ensure business continuity and protect public health. It has also shown us that together we are stronger”. 


Multisector partnerships, DHL said, enabled rapid, effective vaccine distribution. While international scientists developed a vaccine in record time—five times faster than any other vaccine in history—manufacturers ramped up production and logistics teams rolled out distribution three times faster than expected. When commercial routes faced backups, logistics operators worked with military officers to transport vaccines via helicopters and boats. 


In the UAE, the public-private HOPE Consortium distributed billions of COVID-19 doses to its civilians as well as other countries in need by partnering with commercial organisations such as DHL. For the first time, apropo for an unprecedented pandemic, logistics companies made strong connections with public health and government.


“While the race against the virus continues, leveraging the power of such collaborations and data analytics will be key”, said Katja Busch, Chief Commercial Officer DHL and Head of DHL Customer Solutions & Innovation. “We need to remain prepared for high patient and vaccine volumes, maintain logistics infrastructure and capacity, while planning for seasonal fluctuations by providing a stable and well-equipped platform for the years to come”. 


How Do We Sustain Immunisation? 

By the end of 2021, experts estimate that we need approximately 10 billion doses of vaccines—many of which will be shipped to areas of the world, such as India, South Africa, and Brazil, that lack significant infrastructure. This is perhaps the greatest divide between countries that have rolled out successful immunisation programmes and those that have not. As Busch noted, “the UAE’s significant investments in creating robust air, sea, and land infrastructure facilitated logistics and vaccine distribution, helping us keep supply chains resilient”. 


Neither is the novel coronavirus a one-time affair. If predictions hold, COVID will be similar to seasonal colds or the flu: here to stay. When fall comes around each year, governments will need to vaccinate the world as quickly as possible to ensure long-term immunisation against the virus. This time, logistics companies must be better prepared. 

Yet global immunisation, year after year, is no small order. To keep reinfection rates low and slow the spread of COVID, governments will likely need 7-9 billion annual doses of the vaccine to meet that mark. And if DHL’s white paper is any judge of success, multi-sector supply chain partnerships will set the gold standard.

Share article